Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients
Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected for residency in the Bayer Co.Lab incubator in Berlin.
The Bayer Co.Lab program supports cutting-edge biotech and life science innovators by providing access to fully equipped state-of-the-art lab and office infrastructure, global expertise, and Bayer’s broader life science ecosystem. Located at the headquarters of Bayer’s Pharmaceuticals Division, Bayer Co.Lab Berlin is a key hub in the company’s global incubator network, built to accelerate breakthrough technologies on their path to patients.
tiakis Biotech AG Announces Appointment of ex-Actelion Executive Christoph Schmidt as New Supervisory Board Member
– Successful track record in the commercialization of biopharmaceutical products as well as strategic advisory in orphan diseases
tiakis Biotech AG, a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that Dr. Christoph Schmidt has been appointed to the Company´s Supervisory Board.
Dr. Schmidt is a global senior executive with nearly three decades of experience in the biotechnology, pharmaceutical, and life sciences industries. During his leadership roles at Actelion and Johnson & Johnson, he launched four global blockbuster products, three of them in the rare disease Pulmonary Arterial Hypertension (PAH). Read more…
Thermosome Receives U.S. Orphan Drug Designation for Lead Compound THE001, Expands Patent Estate
— ODD granted for the treatment of soft tissue sarcomas (STS)
— Thermosome adds 4 patents to its growing patent estate
Thermosome, a drug development company focused on targeted tumor therapies, today announced that its lead compound, THE001, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of soft tissue sarcomas (STS). This designation complements the ODD already granted by the European Medicines Agency (EMA) and validates the clinical potential of THE001. Read more…
